Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Other Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncomeExpenseNet.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — other operating income of $6.94M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income increased by 35.5% year-over-year, from $5.12M to $6.94M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — other operating income has grown at a 9.8% compound annual growth rate (CAGR), from $3.96M to $5.24M.
- What does affordable medicines — other operating income mean?
- Captures miscellaneous operating income or expenses that do not fall into standard categories like cost of goods sold or SG&A. This includes ancillary revenue streams or minor operational costs essential for assessing the segment's core operational efficiency.